An invisible barrier at the moment a newborn is most defenseless
Newborns and infants under six months saw the most dramatic decline, with hospitalizations plummeting 88.3% from 515 cases to just 60 cases. The RSV vaccine for pregnant women transfers maternal antibodies to babies, providing protection during their most vulnerable early months of life.
- 83.5% drop in RSV hospitalizations among children under two in Paraná between early 2025 and early 2026
- Newborns under six months saw 88.3% reduction: 515 cases down to 60
- 47,213 vaccine doses administered by May 2026, reaching 87.12% coverage among pregnant women
- Zero deaths recorded in the 7-23 month age group during 2026
- 5,380 doses of nirsevimab monoclonal antibody administered since February 2026
Paraná state reports an 83.5% drop in RSV-related hospitalizations among children under two years following a maternal vaccination campaign launched in December 2025, with coverage reaching 87.12%.
In the first five months of 2026, the state of Paraná in southern Brazil has documented a striking reversal in one of childhood's most dangerous seasonal threats. Hospitalizations for severe respiratory illness caused by respiratory syncytial virus—RSV—among children under two years old have collapsed by 83.5 percent compared to the same period last year. The state health department attributes the drop directly to a maternal vaccination campaign that began in December 2025, when pregnant women started receiving a single-dose vaccine designed to transfer protective antibodies to their newborns before birth.
The numbers tell a story of prevention working at scale. Newborns and infants under six months experienced the steepest decline: hospitalizations fell from 515 cases in early 2025 to just 60 in the equivalent period this year—an 88.3 percent drop. Among older infants between seven months and nearly two years, admissions fell from 388 to 89, a 77 percent reduction. Across the entire population of children under two, the total number of hospitalized patients fell from 903 to 149. Perhaps most significantly, the state recorded zero deaths in the seven-month to two-year age group during 2026, a measure of protection that extends beyond hospital beds to the most fragile lives.
The vaccine works by a simple biological principle: a pregnant woman receives the immunization starting at her 28th week of pregnancy, and her body produces antibodies that cross the placenta to her developing child. When the baby is born, those maternal antibodies provide immediate defense against RSV during the first months of life, when infants are least able to fight off severe respiratory infection. By May 2026, Paraná had administered 47,213 doses of the vaccine, achieving a coverage rate of 87.12 percent among pregnant women in the state—a remarkably high adoption rate for a newly introduced intervention.
César Neves, the state health secretary, framed the results as vindication of deliberate public health planning. He stated that the vaccination decision had proven correct and had saved lives, freeing up hospital beds while protecting children against a virus that historically strikes hardest during cold months when bronchiolitis and pneumonia surge. The state, he suggested, had demonstrated the power of coordinated health strategy.
Paraná has layered a second protective tool onto the vaccination campaign: nirsevimab, a monoclonal antibody that provides immediate, direct protection. Unlike the vaccine given to pregnant women, nirsevimab is administered directly to newborns and young children who face the highest risk—premature infants born before 37 weeks of gestation and children up to 23 months old with serious underlying conditions like congenital heart disease, chronic lung disease, or immune system disorders. Since the drug became available through the public health system in February 2026, the state has administered 5,380 doses across two formulations. The combination of maternal vaccination and targeted monoclonal antibody treatment creates what health officials describe as a layered defense: the vaccine builds an invisible barrier at the moment a newborn is most defenseless, while nirsevimab reinforces protection for those at greatest risk.
Maria Goretti David Lopes, the state director of health attention and surveillance, called the convergence of these two technologies a turning point in child health. She emphasized that the vaccination during pregnancy creates protection at the precise moment when newborns cannot yet mount their own immune response, and that the addition of nirsevimab for high-risk groups consolidates what she termed a robust protective network. The results, she noted, depended on the commitment of health teams and the willingness of pregnant women across Paraná to participate in the program.
The story of RSV in Brazil has long been one of seasonal crisis. The virus arrives with cooler weather and spreads rapidly through populations of infants, filling pediatric wards and overwhelming respiratory care capacity. For decades, there was no prevention—only treatment after infection had already taken hold. Now, with a vaccine that works through the biology of pregnancy itself, Paraná has demonstrated that the pattern can be broken. The question facing other Brazilian states, and health systems elsewhere, is whether they will adopt the same approach.
Notable Quotes
The vaccination of pregnant women was a correct decision and saved lives. We freed up hospital beds and protected our children against an infectious agent that historically strikes babies hardest during the cold months.— César Neves, Paraná state health secretary
The vaccine creates an invisible barrier at the moment when the newborn is most defenseless. Combined with nirsevimab for high-risk groups, we have built a robust protective network.— Maria Goretti David Lopes, director of health attention and surveillance
The Hearth Conversation Another angle on the story
Why does RSV hit infants so hard in the first place? What makes them so vulnerable?
Infants under six months have almost no immune system of their own. They can't mount a strong response to viral infection. RSV attacks the small airways in the lungs, causing inflammation and mucus buildup that makes it hard to breathe. For a tiny baby, that's life-threatening. That's why the vaccine targets pregnancy—it's the only window where you can arm the baby before birth.
So the mother's antibodies actually cross the placenta and protect the baby after birth?
Exactly. The vaccine triggers the mother's immune system to produce antibodies against RSV. Those antibodies cross into the baby's bloodstream through the placenta, and they stay there for the first months of life, when the baby is most at risk. It's borrowed immunity, but it works.
The numbers show 88 percent fewer hospitalizations in newborns under six months. That's enormous. Did anyone die?
No deaths were recorded in that age group in 2026. That's the point—RSV used to kill infants regularly during the cold months. Now it doesn't. The vaccine prevented not just hospitalizations but deaths.
What about the nirsevimab? How does that fit into the picture?
It's a different tool for a different moment. The vaccine protects broadly, but nirsevimab is for the babies at highest risk—premature infants and those with serious heart or lung conditions. It's a monoclonal antibody, so it provides immediate protection without waiting for the immune system to respond. You give it once, and it works right away.
Why did it take until December 2025 for Paraná to start this program?
The vaccine itself is relatively new globally. Paraná was among the early adopters. Once they saw the data from other places showing it worked, they made the decision to vaccinate all pregnant women starting at 28 weeks. By May 2026, they'd reached 87 percent coverage—that's remarkable uptake.
What happens next? Does this become permanent?
That's the real question. If the numbers hold, if other states see what Paraná achieved, this becomes standard practice. RSV stops being the seasonal killer it always was. But it requires sustained commitment—vaccination rates have to stay high, and the supply has to be there every year.